Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery
Jun Soo Park,Min Seop Kim,Min Yeong Joung,Hyun Jin Park,Myoung-Jin Ho,Jun Hyuk Choi,Jae Hee Seo,Woo Heon Song,Young Wook Choi,Sangkil Lee,Yong Seok Choi,Myung Joo Kang
DOI: https://doi.org/10.2147/IJN.S375888
IF: 7.033
2022-08-26
International Journal of Nanomedicine
Abstract:Jun Soo Park, 1 Min Seop Kim, 1 Min Yeong Joung, 1 Hyun Jin Park, 1 Myoung-Jin Ho, 1 Jun Hyuk Choi, 1 Jae Hee Seo, 1 Woo Heon Song, 1 Young Wook Choi, 2 Sangkil Lee, 3 Yong Seok Choi, 1 Myung Joo Kang 1 1 College of Pharmacy, Dankook University, Cheonan, Republic of Korea; 2 College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea; 3 College of Pharmacy, Keimyung University, Daegu, Republic of Korea Correspondence: Myung Joo Kang, College of Pharmacy, Dankook University, Dongnam-gu, Cheonan, 31116, Republic of Korea, Tel +82 41 550 1446, Fax +82 41 550 7899, Email Background: Montelukast (MTK), a representative leukotriene receptor antagonist, is currently being investigated as a potential candidate for treating Alzheimer's disease. For potent and effective dosing in elderly patients, a parenteral prolonged delivery system is favored, with improved medication adherence with reduced dosage frequency. Purpose: This study aimed to design a nanocrystalline suspension (NS)-based MTK prolonged delivery system and evaluate its pharmacokinetics profile and local tolerability following subcutaneous administration. Methods: To decelerate the dissolution rate, the amorphous MTK raw material was transformed into a crystalline state using a solvent-mediated transformation method and subsequently formulated into NS using a bead-milling technique. The MTK NSs were characterized by morphology, particle size, crystallinity, and in vitro dissolution profiles. The pharmacokinetic profile and local tolerability at the injection site following subcutaneous injection of MTK suspension were evaluated in rats. Results: Microscopic and physical characterization revealed that the amorphous MTK powder was lucratively transformed into a crystalline form in acidic media (pH 4). MTK crystalline suspensions with different diameters (200 nm, 500 nm, and 3 μm) were uniformly prepared using bead-milling technology, employing polysorbate 80 as suspending agent. Prepared crystalline suspensions exhibited analogous crystallinity (melting point, 150°C) and size-dependent in vitro dissolution profiles. MTK NSs with particle sizes of 200 nm and 500 nm provided a protracted pharmacokinetic profile for up to 4 weeks in rats, with a higher maximum drug concentration in plasma than the 3 μm-sized injectable suspensions. Histopathological examination revealed that MTK NS caused chronic granulomatous inflammation at the injection site, which resolved after 4 weeks. Conclusion: The MTK parenteral NS delivery system is expected to be a valuable tool for treating Alzheimer's disease with extended dose intervals. Graphical Keywords: montelukast, parenteral prolonged release delivery, crystallinity, nanocrystalline suspension, bead-milling, pharmacokinetics, local tolerability Graphical Alzheimer's disease (AD) is a prominent neurodegenerative disease characterized by a gradual decline in cognitive ability and memory loss. 1 Although AD's pathogenesis is not completely understood, the tau protein aggregation and intraneuronal neurofibrillary tangle formation, extracellular senile plaques, neuronal loss, microglial, and neuroinflammatory reactions have been considered the main neurodegenerative disease hallmarks. 2–7 Recent studies have supported the positive effect of cysteinyl leukotriene type 1 (cysLT-1) receptor antagonists on inflammatory responses in the brain, neuronal injury, blood-brain-barrier (BBB) integrity, and accumulation of amyloid-β42 (Aβ) protein. 8–10 Montelukast (MTK), a representative leukotriene antagonist, has been prescribed for chronic asthma and seasonal allergy treatment. 10 Oral therapy is being clinically investigated as an alternative medication for Alzheimer's disease. 11–15 MTK is included in oral dosage forms in the amorphous state to provide rapid and profound dissolution and intestinal absorption of the hydrophobic compound (log P value of 8.4). 16 It was rapidly absorbed upon oral administration, exhibiting a maximum plasma concentration (C max ) within 3–4 h, with approximately 66% oral bioavailability in healthy subjects. 17 However, when considering its potent prescription for Alzheimer's patients with poor medication adherence, a parenteral prolonged delivery system offering an effective therapeutic level for several weeks following a single administration can be favored with extended dosing intervals. 18 Previously, biodegradable polymeric microparticle system has been designed for prolonged delivery of MTK, providing -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology